Signaling pathways
-
BA1883 SetrobuvirSummary: Setrobuvir (ANA598) is an orally active non-nucleoside polymerase inhibitor. - BA1886 Nucleoside-Analog-1Summary: Nucleoside-Analog-1, an analog of antiviral nucleoside R1479, was used in the synthesis of HCV antiviral nucleoside analogs.
- BA1887 KIN1400Summary: KIN1400 is a potent activator.
-
BA1891 VoxilaprevirSummary: Voxilaprevir (GS-9857) is a non-covalent, reversible protease inhibitor (PI) with pan-antiviral activity. - BA1892 JTK-109Summary: JTK-109 is a potent inhibitor of hepatitis C virus RNA-dependent RNA polymerase.
- BA1895 ABBV-744Summary: ABBV-744 is a first-of-its-kind, orally active and selective BDII structural domain of the BET family of proteins.
- BA1896 BictegravirSummary: Bictegravir (GS-9883) is a potent integrase inhibitor.
- BA1897 CenicrivirocSummary: Cenicriviroc (TAK-652) is an orally available dual antagonist.
- BA1898 TAK-779Summary: TAK-779 is a potent, selective, non-peptide and antagonist.
- BA1899 FangchinolineSummary: Fangchinoline has a wide range of biological activities such as immune-enhancing, anti-inflammatory and antiseptic, and anti-atherosclerotic.